D-amino acid proteins as a new class of pharmaceutical products
Dana Ault-Riche
CEO, Reflexion Pharmaceuticals
Small proteins composed entirely of D-amino acids enhance the advantages of small proteins, such as high tissue and tumor penetration rates, smaller dose volumes, and multi-specific formats, by enabling greater stability, longer half lives and reduced immunogenicity. Chemical protein synthesis combined with mirror image phage display has been used to produce potent inhibitors of VEGF-A and other therapeutic targets. The role of stereochemistry in immune responses and recent progress in the development of D-amino acid proteins as therapeutics will be presented.